A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 4, 2021

Primary Completion Date

July 15, 2022

Study Completion Date

May 4, 2023

Conditions
Acromegaly
Interventions
DRUG

GHR-LRX

GHR-LRX was administered by SC injection.

Trial Locations (22)

4032

Debreceni Egyetem Klinikai Kozpont, Debrecen

10065

Memorial Sloan Kettering Cancer Center, New York

10138

East-Tallinn Central Hospital, Tallinn

11000

Clinical Center of Serbia, Belgrade

20122

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan

21000

Clinical Center of Vojvodina, Novi Sad

43201

Endocrinology Associates, Inc, Columbus

44195

Cleveland Clinic, Cleveland

50161

Hospital of Lithuanian University of Health Sciences (LSMU) Kauno klinikos, Kaunas

50406

Tartu University Hospital, Tartu

63246

Vaidoto Urbanaviciaus Individuali imone, Alytus

89148

Palm Research Center Inc., Las Vegas

90048

Cedars-Sinai Medical Center, Los Angeles

97239

Oregon Health & Science University (OHSU), Portland

119146

I.M. Sechenov Moscow First State Medical University, Moscow

02114

Massachusetts General Hospital, Boston

00168

Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Roma

LV-1002

Pauls Stradins Clinical University Hospital, Riga

03-242

Zespol Oddzialow Chorob Wewnetrznych, Endokrynologii i Diabetologii, Warsaw

50-556

Uniwersytecki Szpital Kliniczny, im. Jana Mikulicza-Radeckiego we Wroclawiu,, Wroclaw

51-162

Centrum Badan Klinicznych Piotr Napora Lekarze Sp. p., Wroclaw

060044

Centrul Medical Unirea Bucuresti, Endocrinologie, Bucharest

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY